TY  - GEN
AU  - Green,Brian
TI  - Metabolomics in Neurodegenerative Disease
SN  - books978-3-03928-041-4
PY  - 2020///
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - glutamic acid
KW  - n/a
KW  - direct mass spectrometry
KW  - neurodegeneration
KW  - 6-OHDA
KW  - targeted mass spectrometry
KW  - mitochondrial dysfunction
KW  - myo-inositol
KW  - metabolomics
KW  - bile acids
KW  - subacute mild traumatic brain injury
KW  - age-related macular degeneration
KW  - metabolic pathways
KW  - energy metabolism
KW  - midbrain
KW  - Alzheimer's disease
KW  - biomarkers
KW  - 1H NMR
KW  - Parkinson's disease dementia
KW  - GC-MS
KW  - pathogenesis
KW  - tricarboxylic acid cycle
KW  - micro-dialysis
KW  - 13C-labeled succinate
KW  - metabolism
KW  - lipidomics
KW  - dementia with Lewy bodies
KW  - fatty acid
KW  - prodromal Parkinson's disease
KW  - malonate
KW  - cerebral ischemia
KW  - mass spectrometry
KW  - retinal pigment epithelium
KW  - excitotoxicity
KW  - endothelin-1
KW  - reperfusion
KW  - C. elegans
KW  - Streptomyces venezuelae
KW  - ?-synuclein aggregates
KW  - natural product
KW  - fatty acid metabolism
KW  - imaging mass spectrometry
KW  - LC-MS
KW  - drusen
KW  - cerebral palsy
KW  - plasma
KW  - Parkinson's disease
N1  - Open Access
N2  - The range of human neurodegenerative diseases continues to pose significant unmet medical needs for societies around the world. The progressive and terminal nature of these conditions places a considerable personal burden on the individual affected but also on public health systems and health services. Tens of millions of people are indiscriminately affected by various dementias, which are rising at an alarming rate. There are no cures for many conditions, and it is clear that treatments applied as early as possible could greatly improve outcomes for patients. Therefore, new disease classification and diagnostic tools should be a key priority. Metabolomics represents a relatively new field of analytical science, which can be extremely useful in the early diagnosis of disease. The relatively unique feature of metabolites is that they sit at the intersection between the genetic background of an organism and its environment. Because many neurodegenerative diseases are not genetically inherited (instead having a range of known genetic risk factors and also a large number of unknown environmental triggers) the field of metabolomics offers great promise for the discovery of new, biologically, and clinically relevant biomarkers for neurodegenerative disorders. It is already bringing forward new knowledge in terms of the mechanisms of neurodegenerative disease
UR  - https://mdpi.com/books/pdfview/book/2226
UR  - https://directory.doabooks.org/handle/20.500.12854/53236
ER  -